For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 9,373 | 23,239* | 9,073 | 6,575 |
| Acquired in-process research and development, related party | - | 0* | 0 | 0 |
| General and administrative | 5,838 | 6,289* | 5,819 | 4,102 |
| Total operating expenses | 15,211 | 29,527 | 14,892 | 10,677 |
| Loss from operations | -15,211 | -29,527* | -14,892 | -10,677 |
| Interest income | 1,514 | 2,007* | 2,037 | 2,173 |
| Foreign currency (gain) | -25 | 2* | -33 | -162 |
| Total other income (expense) | - | 2,008* | - | - |
| Total other income, net | 1,489 | - | 2,004 | 2,011 |
| Net loss attributable to common stockholders | -13,722 | -27,519* | -12,888 | -8,666 |
| Unrealized gain (loss) on marketable securities | -278 | 138* | 151 | 32 |
| Comprehensive loss | -14,000 | -27,382 | -12,737 | -8,634 |
| Basic EPS | -0.2 | -0.404 | -0.19 | -0.13 |
| Diluted EPS | -0.2 | -0.404 | -0.19 | -0.13 |
| Basic Average Shares | 68,207,313 | 67,848,066 | 68,003,248 | 67,585,121 |
| Diluted Average Shares | 68,207,313 | 67,848,066 | 68,003,248 | 67,585,121 |
Climb Bio, Inc. (CLYM)
Climb Bio, Inc. (CLYM)